Martin, M.
Zielinski, C.
Ruiz-Borrego, M.
Carrasco, E.
Turner, N.
Ciruelos, E.M.
Muñoz, M.
Bermejo, B.
Margeli, M.
Anton, A.
Kahan, Z.
Csöszi, T.
Casas, M.I.
Murillo, L.
Morales, S.
Alba, E.
Gal-Yam, E.
Guerrero-Zotano, A.
Calvo, L.
de la Haba-Rodriguez, J.
Ramos, M.
Alvarez, I.
Garcia-Palomo, A.
Huang Bartlett, C.
Koehler, M.
Caballero, R.
Corsaro, M.
Huang, X.
Garcia-Sáenz, J.A.
Chacón, J.I.
Swift, C.
Thallinger, C.
Gil-Gil, M.
Funding for this research was provided by:
AstraZeneca
Pfizer
This article is maintained by: Elsevier
Article Title: Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL
Journal Title: Annals of Oncology
CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.annonc.2020.12.013
Content Type: article
Copyright: © 2020 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.